Status Plus




Sexual functioning in people taking antidepressants and healthy volunteers in Japan: A cross sectional online survey

McDougall, F1; Gibbs, A2; Le Scouiller, S1; Sato, A3; Aoki, M3; Takano, K3; Chiba, A3; Kawana, T3Clayton, AH4

1: Roche Products Ltd, United Kingdom; 2: Eisai Europe, UK; 3: Chugai Pharmaceutical Co., Ltd, Japan; 4: Dept of Psychiatry and Neurobehavioral Sciences, University of Virginia, USA

Objectives. Sexual dysfunction is a common feature in depression and a known side effect of antidepressants. Few studies have examined this issue in Asian populations and the validity of existing instruments used to measure sexual dysfunction is not well established. The aims of this study were: (1) to evaluate the utility of the Japanese version of the 14-item Changes in Sexual Functioning Questionnaire (CSFQ-14) in measuring sexual functioning in patients taking antidepressants and healthy volunteers in Japan and (2) to investigate the prevalence of sexual dysfunction amongst outpatients taking antidepressants in Japan.

Methods. 100 outpatients taking antidepressants and 100 healthy volunteers were recruited with a 1:1 ratio of male to female participants. Participants completed an online survey of current sexual functioning including the CSFQ-14 and additional questions about problems with sexual functioning.

Results. CSFQ-14 mean total scores were significantly lower in male patients (39.5 C.I. 37.5-41.6) than in male healthy volunteers (47.3, C.I. 45.1-49.5, t=-5.16, p<.0001). Based on the non-overlap of the 95% confidence intervals, a Japan-specific cut-off score on the CSFQ-14 of ≤ 43 was proposed in men. Using this threshold, significantly more antidepressant users (72%, CI 60-84%) than healthy participants (34%, CI 21-47%) had clinically significant sexual dysfunction (Chi-sq=14.49, p<.0001). In women, mean total CSFQ-14 scores were not significantly different between healthy volunteers (35.0, C.I. 32.6-37.3) and patients on antidepressants (34.6, C.I. 32.0-37.2, t=-0.23, p=.82). It was not possible to define a Japan specific cut-off score for sexual dysfunction in women.

Conclusions. Our study suggests the CSFQ-14 can be used to measure sexual dysfunction and to determine the proportion with a clinically significant level of dysfunction in Japanese men. However, the CSFQ-14 did not distinguish between women on antidepressants and those that were not, suggesting further research is required to ascertain the reasons (e.g. possibly cultural factors) and how best to measure sexual dysfunction in Japanese women.


Work supported by industry: yes, by Chugai Pharmaceutical Co & Roche Products Ltd (industry initiated, executed and funded study). The presenter or any of the authors act as a consultant, employee (part time or full time) or shareholder of an industry.

Go Back